Notice of General Meeting
Released
Released
Announcement PDF
ABN 41 095 060 745
NOTICE OF MEETING BOOKLET
INCORPORATING DIRECTORS’ STATEMENT, NOTICE OF MEETING, EXPLANATORY
MEMORANDUM, PROXY FORM AND MEMBER’S STATEMENT
Meeting to be held at
MinterEllison
Governor Macquarie Tower
Level 40/ 1 Farrer Place
Sydney, NSW, 2000
on
Thursday, 24 April 2025
commencing at
4:00 pm (AEST)
The Directors of Percheron Therapeutics Limited unanimously
recommend
Shareholders vote their Shares:
AGAINST all six resolutions
This is an important document that requires your immediate attention.
You should read this document in its entirety before deciding whether to vote for or against any resolution at
the Meeting. If you are in doubt as to how you should vote, you should seek advice from your accountant,
solicitor or other professional adviser prior to voting.
If you have questions about the Meeting or the resolutions to be voted on, please contact the Company
Secretary, Ms Deborah Ambrosini on +61 411 828 748 or deborah.ambrosini@percherontx.com.
Statement by the Directors of
Percheron Therapeutics Limited
Issued in response to the call for a General Meeting of the
Members of the Company by Powerhouse Ventures Limited
14 March 2025
Contents
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
CONTENTS
1.
Summary of Key Points .......................................................................................................... 2
2.
Letter from the Board of Directors .......................................................................................... 3
3.
Background .......................................................................................................................... 5
4.
Response to the Statement by Powerhouse Ventures ........................................................... 10
5.
The Board’s Strategy to Rebuild Shareholder Value ............................................................... 17
6.
Concluding Remarks ........................................................................................................... 20
Page 1 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
1. SUMMARY OF KEY POINTS
1.
Percheron Therapeutics Limited (‘Percheron’ or the ‘Company’) has received a
notice from Powerhouse Ventures Limited (ASX: PVL) (‘Powerhouse’) under
section 249D of the Corporations Act proposing resolutions that, if passed at a
General Meeting, would result in all the current Directors being replaced with
Powerhouse nominees.
2.
The proposal would see Powerhouse gain absolute control of the Company’s
assets, including its cash reserves of $17.6 million (as at 31 December 2024).
3.
Powerhouse has provided shareholders with no concrete detail on what its
proposed directors would do differently from the current Directors. However, in
discussions with the Percheron Board, Powerhouse has described a model where
they would direct the Company to ‘invest’ its capital in other companies and
projects that Powerhouse would nominate. The Percheron Board considers this
strategy unlikely to provide an optimal outcome for Percheron shareholders.
4.
The Board recognises that the negative outcome of the phase IIb trial of ATL1102
in Duchenne muscular dystrophy has been a profoundly disappointing
experience for all Percheron’s stakeholders. The Directors are determined to
rebuild shareholder value, and that means charting a new course for the
Company.
5.
To that end, the Percheron Board has identified a specific asset that it proposes
to in-license. The asset, which is clinic-ready, addresses a neurological illness
with very high unmet clinical need. The Board believes that Percheron can
generate meaningful catalysts with current funds on hand. Comparative
companies are generally well-valued in the market, suggesting considerable
potential upside for Percheron shareholders.
6.
In the meantime, the Directors are ‘walking the talk’. They have bought a
considerable amount of stock in the open market to signal their support of
Percheron and now hold more than 4% of the issued share capital. The CEO has
offered, and the Board has agreed, to defer 50% of his salary through this
transitional period, and certain Director fees have been similarly deferred. The
Company’s cost base has been substantially reduced.
7.
Percheron is well-positioned to recover from the events of the past few months,
but it will only do so with the continued support of its shareholders. You are faced
again with a critical choice as to the Company’s future. Please vote AGAINST the
resolutions proposed by Powerhouse and, in so doing, for a prosperous and
successful future for your Company.
Page 2 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
2. LETTER FROM THE BOARD OF DIRECTORS
Dear Shareholder,
It is extremely regrettable that Percheron and its shareholders must once
again confront a hostile attempt to take over control of the Company.
Powerhouse, a microcap listed fund based in Brisbane, has called for a
General Meeting of the Company’s members to remove all three of the
existing Directors, Dr Charmaine Gittleson, Dr Gil Price, and Dr James
Garner, and to replace them with three directors of their own, Mr Doran
Eldar, Mr Julian Chick, and Mr David Hammersley.
Shareholders have already
made their wishes clear in
the General Meeting of
4 March 2025, in which all
resolutions to remove
Directors failed
We are truly sorry that shareholders are being subjected to this
unwelcome distraction for the second time. You have made your wishes
clear, in the General Meeting that was held on 4 March 2025, that you
wish to see the current Board given the opportunity to deliver on the
strategy it has laid out for the Company. Unfortunately, Powerhouse has
failed to listen to that message. As a consequence, we must ask you one
more time to come to the defence of the Company.
We were prepared to believe that the previous General Meeting
requisition, in which Mr Gennadi Koutchin and Mr Gregory Peters were
unsuccessful in their attempt to seize control of the Board, was born out
of the shock and disappointment that we all experienced following the
negative read-out of the phase IIb study of ATL1102 in Duchenne
muscular dystrophy. It is impossible to extend the same benefit of the
doubt to this new attempt by Powerhouse.
Powerhouse proposal
would result in a Board
composed entirely of their
appointees
Its holding in the Company has been largely accumulated since the trial
result was announced, and it seems clear that this is an opportunistic
and profoundly cynical attempt to take advantage of the Company’s
temporarily weakened state. Its proposal would result in the entire Board
being composed of Powerhouse’s own appointees, despite them holding
only 10% of the stock, with no representation for the remaining
shareholders who hold the other 90% of the shares.
If Powerhouse wishes to take control of Percheron’s assets, including its
substantial cash reserves, we believe that it should put a fair and
reasonable offer to shareholders for their consideration. As a Board, we
would consider it in good faith and put it to you for your consideration.
However, for Powerhouse to attempt a takeover by stealth, by seizing
control of the Company’s Board, is deeply disrespectful of shareholders’
rights and interests.
Since the trial result was announced on 18 December 2024, we have
made very good progress in rebuilding the Company. The data from the
trial has been exhaustively analysed and was presented to investors on 6
February 2025. It showed that the trial was well-designed and well-
Page 3 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
conducted, and that ATL1102 was simply not potent enough to change
the outcome in a very aggressive disease such as Duchenne.
Percheron has submitted
an offer for a compelling
new asset and is in
detailed confidential
negotiations
Recognising that Percheron would not be investable with ATL1102 as its
centrepiece, the Board stepped up already ongoing efforts to in-license
one or more new assets. To this end, we have submitted a non-binding
offer on a program that we think represents a compelling opportunity for
the Company’s shareholders, and we continue to advance negotiations
as rapidly as possible, despite the disruption caused by Powerhouse.
This General Meeting will, in effect, ask what kind of company you want
Percheron to be. Our vision for the Company is simple. We want to
deliver impactful new medicines to patients confronting devastating
illness and, in doing so, we want to restore and increase the value of your
investment in the Company. We ask you again to give us the opportunity
to complete these turnaround efforts.
Percheron Directors have
bought on market in
support of the stock
We are not just talk – we have backed ourselves to the extent of having
invested hundreds of thousands of dollars of our own funds in
Percheron. We are determined to demonstrate to you that we have the
capability and the tenacity to make the Company a stronger business
than it ever was. To that end, we implore you to vote AGAINST all
resolutions put forward at this meeting. Every vote counts, no matter
how large or small your holding, so please make sure that your voice is
heard.
We thank you in advance for your ongoing support.
Yours faithfully,
Dr Charmaine Gittleson
Chair of the Board
Dr Gil Price
Non-Executive Director
& Chair of Audit
Page 4 of 21
Dr James Garner
Managing Director
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
3. BACKGROUND
1. Powerhouse Ventures Limited
The Powerhouse website describes the company as a “high conviction,
speciality investment house, with an expanding range of funds,
management products, advisory and capital syndication services, and
investor relations support.”1
Powerhouse is
approximately the same
size as Percheron
Powerhouse is, by any standard of reckoning, a small operation. As of 28
February 2025, its market capitalisation on the ASX is $13.0 million. By
contrast, Percheron, even after the decrease in share price associated
with the negative read-out of the ATL1102 phase II study, was valued at
$12.0 million at the same date. If Powerhouse were to gain control of the
Percheron Board, it would effectively double the combined size of its
enterprise, when measured by market capitalisation.
Powerhouse emphasises its capabilities in corporate advisory and
investor relations, but the market attributes no meaningful value to these
operations. As at 31 December 2024, which is the most recent date for
which financial reports are available, the company’s net tangible assets
(NTA) per share were valued at 10.4 cents.2 On the same day, the
company’s share price closed at 9.4 cents. This implies that investors
attribute negative value to Powerhouse itself, in the approximate amount
of minus 1.0 cent per share. If the company were to simply distribute its
net tangible assets to shareholders, they would be worth more in their
hands than they are in the hands of Powerhouse.
Powerhouse reported only
~$2 million of cash at 31
December, versus $17.6
million at Percheron
Powerhouse shares are
essentially flat over the
past three years
1
2
At the same reporting date, Powerhouse had only $2.05 million of cash at
the bank. It is easy to imagine how attractive Percheron’s cash reserves
of $17.6 million must seem. In the December quarter, Powerhouse
reported just $231 thousand of free cash flow. Were Powerhouse simply
to put Percheron’s $17.6 million in the bank at a 5% interest rate, it would
increase its free cash flow approximately five-fold.
Over the three-year period to 28 February 2025, the price of
Powerhouse’s shares on the Australian Securities Exchange decreased
from $0.096 to $0.095. By contrast, the S&P ASX200 index has increased
over the same period by 14.9%. A shareholder in Powerhouse would
have been around 15% better off over the last three years if they had
simply invested their money in a passive index-tracking fund. A
shareholder in Percheron, meanwhile, may reasonably ask why they
should believe that Powerhouse would build sustainable long-term
shareholder value in this company when they have not yet demonstrated
such an ability in their own.
Powerhouse Ventures corporate website (https://www.phvl.com.au) – accessed on 25 February 2025
PVL Announcement to ASX of 23 January 2025
Page 5 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
Powerhouse is not a specialist life sciences investor, nor does it appear
to invest primarily in public companies. Its most recent AGM
presentation mentions a number of investments, including Skykraft Pty
Ltd (“space enabled air traffic management”), RegenCo Pty Ltd (“helping
landholders diversify their revenue streams through the creation and
sale of carbon credits”), Inhibit Coatings Pty Ltd (“using smart chemistry
to permanently bind antimicrobial silver to materials”), Cirrus Materials
Science (“advanced coatings to reduce cost and drive performance”),
and Quantum Brilliance Pty Ltd (“room temperature diamond quantum
accelerators”).3 Of the investments listed, only Ferronova Pty Ltd is in the
healthcare space, and its business is focused on a diagnostic imaging
product, which is a very different endeavour to drug development. Put
simply, Powerhouse does not have demonstrable in-house expertise in
the type of business to which Percheron belongs.
Powerhouse’s investment
model relies in part on
securing fee income from
portfolio companies
July
2024
September
2024
December
2024
However, Powerhouse is not an entirely conventional investor, in the
sense that its investment returns do not necessarily derive from an
increase in the value of its investments. Rather, the business model of
Powerhouse includes what it refers to as ‘active sponsorship’, in which
the fund extracts advisory and other fees from its portfolio companies. In
a strictly financial sense, this is advantageous to Powerhouse (since it
receives a greater return) but may be disadvantageous to all other
shareholders (since the fees either dilute their holding, if in equity, or
draw down the capital they have invested, if in cash). Some examples of
such transactions include:
Invested $500,000 in Australian
Carbon Credits Investments Pty Ltd
(PRIVATE)
Invested $300,000 in Site Group
International (ASX: SIT)
PVL receives ‘additional founder equity’
through ‘active sponsorship’ of ACCI, and
chairs Board of Directors4
PVL receives unspecified ‘arrangement fee’
and retained advisory fees for two years5
Invested $200,000 in US-based
Metal Powder Works, followed by
reverse listing into K-TIG (ASX:KTG)
PVL receives $110,000 in fees6
Powerhouse’s ‘active sponsorship’ has not been of benefit to at least one
of these investments. On 26 February 2026, Site Group International
(ASX: SIT) went into a voluntary suspension of trading on ASX, which a
subsequent announcement explained was due to the risk that penalties
imposed by the Australian Competition and Consumer Commission
(ACCC) may be as much as tenfold higher than the $1.1 million
provisioned in their accounts.7 On 3 March 2025, the company’s
securities were again suspended from trading by ASX under Listing Rule
17.5 after it failed to lodge a half-year report.
PVL Announcement to ASX of 21 November 2024
PVL Announcement to ASX of 9 July 2024
5
PVL Announcement to ASX of 25 September 2024
6
PVL Announcement to ASX of 23 December 2024
7
SIT Announcement to ASX of 27 February 2025
3
4
Page 6 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
2. Summary of Percheron’s Discussions with Powerhouse
In January 2025, Dr Gittleson and Dr Garner met with Powerhouse in
Brisbane. In attendance at the meeting were James Kruger, Chair of the
Board at Powerhouse, David McNamee, the fund manager at
Powerhouse with responsibility for its investment in Percheron, and
Doron Eldar, a non-executive director at Powerhouse.
At this first meeting, the Powerhouse directors indicated an interest in
working with the Percheron Board to rebuild the Company. They
advocated a different business model which entailed Percheron, under
the oversight of Powerhouse, deploying its cash reserves to make small
investments across multiple companies in the global healthcare sector.
Powerhouse have been
attempting to secure
influence over Percheron
Board since early January
However, Powerhouse’s true intent soon became apparent when they
indicated a desire to control the Percheron Board. They demanded the
immediate appointment of a director of their choice, nominating Mr
Elder for this purpose. They began referring to a ‘supervisory committee’
or ‘investment committee,’ which would sit over the Percheron Board,
and which would direct it in investing the Company’s funds in other
entities.
While concerned about the model proposed, Dr Gittleson and Dr Garner,
acting in good faith, requested a follow up meeting with Mr Kruger, Mr
McNamee, and Mr Eldar in the hope of obtaining more concrete detail
around the Powerhouse proposal. A videoconference was held in
February 2025 with Mr Kruger only participating for the first half an hour.
The Percheron Directors described the Board’s strategy to in-licence a
new asset with the potential to create a pipeline and stated that, in the
absence of a detailed proposal from Powerhouse, the Board considered
it was the best way to restore shareholder value. Mr McNamee indicated
his opposition to this approach and proffered that Percheron was “one of
the richest shells on the ASX.”
Powerhouse have
advocated that Percheron
invest its cash reserves in
companies that
Powerhouse would
nominate
Mr McNamee and Mr Eldar expanded on their vision for Percheron in
which the Company would largely cease the business of drug
development and would instead invest its cash reserves in other
businesses chosen by Powerhouse’s appointed investment committee,
with Percheron paying consulting fees to Powerhouse. In addition,
Powerhouse would receive corporate advisory fees and capital raising
fees from the various entities in which Percheron invested. Mr Eldar also
stressed the significant fees that could be made from convertible notes,
although these fees would presumably accrue primarily to Powerhouse.
The Powerhouse team described their model idiosyncratically as
‘merchant banking’.
In considering the points put forward by Powerhouse, the Percheron
Board raised a number of concerns with the proposed business model:
Page 7 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
The Percheron Board does
not believe that
Powerhouse’s proposed
model would be in the
interests of Percheron
shareholders
1. Since the Company was a drug development business, not an
investment business, and given that the ‘investment committee’
would effectively represent a group of ‘shadow directors,’ the model
would likely fall short of the corporate governance standards
expected by Percheron’s many stakeholders.
2. The very limited detail provided by Powerhouse did not make clear
how the model would generate value for Percheron shareholders,
given that any such investments would be (a) small, (b) unlikely to
secure control or even influence over the target companies, (c)
illiquid, and (d) unlikely to generate any near-term return. Neither Mr
Eldar nor Mr McNamee could elaborate on this to reassure the
Percheron board, other than referring obliquely to Mr Eldar’s prior
experience in the healthcare sector.
3. The model presented lacked sufficient detail to determine its merit
and allow the Percheron board to deliver on its fiduciary duty to
shareholders.
Dr Gittleson stressed that Percheron could not reasonably pursue such a
major change to the Company’s business activities without a compelling
business plan, and without being satisfied that any such change was in
the best interests of shareholders. She requested the Powerhouse
attendees provide documents to the Company to better explain their
proposed business model, to which Powerhouse agreed.
Despite undertaking to
provide more detailed
proposals, Powerhouse
launched an attempt to
take over the Percheron
Board
Unfortunately, no such documents were provided and on 21 February
2025, Percheron received a notice from Powerhouse under section 203D
of the Corporations Act, in which Powerhouse put forward proposed
resolutions for the removal of Directors at a proposed General Meeting of
shareholders.
Mr McNamee subsequently clarified that Powerhouse elected to take
this route as their primary concern was that Percheron would in-license
a new asset and would rebuild itself as a drug development business.
During the initial conversations held between the two companies in
January and February, Powerhouse declared their support for Dr
Gittleson and Dr Garner but advised that they desired to remove Dr Gil
Price from the Percheron Board, a point with which the other Directors
did not agree.
Powerhouse threatened to
vote tactically in the
Koutchin-Peters General
Meeting if their demands
were not met
This position then changed, and Mr McNamee stated that the support of
Powerhouse in the Koutchin-Peters General Meeting may be dependent
on Powerhouse installing one or more of their own directors on the
Percheron Board. The Company responded that it would consider any
proposed director on their merits, and on their ability to further the
interests of all shareholders, but they would not be ‘strong-armed’ into
appointing a director and that, if necessary, the Company would fight –
and win – the Koutchin-Peters General Meeting without the support of
Powerhouse.
Page 8 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
In a subsequent telephone discussion with Dr Gittleson, Mr McNamee
stated that Powerhouse intended to vote tactically in the upcoming
Peters-Koutchin General Meeting to selectively remove Dr Gittleson and
Dr Garner, leaving the Company with an insufficient Board, onto which it
would then advocate to have its chosen directors immediately
appointed.
Despite Powerhouse
voting to remove Dr
Gittleson and Dr Garner at
the Koutchin-Peters
General Meetings, a
majority of shareholders
opposed them
This was indeed their voting. In the Peters-Koutchin General Meeting in
March 2025, Powerhouse voted to remove Dr Gittleson and Dr Garner,
and abstained on the appointment of Mr Peters and Mr Koutchin. A
number of recent new shareholders, some utilising nominee accounts,
voted in the same manner as Powerhouse. Nevertheless, the support of
other shareholders was such that all resolutions at that General Meeting
were not carried.
In summary, Powerhouse’s position, as it has been presented to the
Percheron Board over the past several months, has been inconsistent
and incomplete. At no stage has Powerhouse mentioned the concerns
raised in their formal statement that is included with the notice of
meeting. Rather, their focus has been on ways to gain control of
Percheron and its cash reserves. It is the belief of the Percheron Board
that, were they to do so, they would use the Company’s cash and
corporate shell to support a variety of transactions that would generate
fee income for Powerhouse. While such an outcome may be
advantageous to Powerhouse, the Percheron Board does not believe that
it would be in the interests of Percheron shareholders.
Page 9 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
4. RESPONSE TO THE STATEMENT BY POWERHOUSE VENTURES
The statement by Powerhouse under section 249P of the Corporations
Act is included in the Notice of Meeting, and all shareholders are
encouraged to read it carefully. The Directors make the following
comments and observations.
1. Corrections to Factual Errors in Powerhouse’s Statement
“While the current board and management team were appropriate to
preside over the trials and rollout of the ATL1102 asset, it is now the case,
given the trail’s [sic] failure, that we no longer believe they are the right
team to take the company into its next phase.”
This is disingenuous.
Powerhouse bought the
majority of its holding after
announcement of the
negative ATL1102 trial
result
Of the 110 million shares registered to Powerhouse as at 28 February
2025, approximately 90% were purchased after the announcement of
the ATL1102 phase 2B trial data on 18 December 2024. Why did
Powerhouse buy more than a million dollars of stock in Percheron if they
believed that the Board and management of the Company were not the
right team to oversee the Company? It is hard to avoid the conclusion
that their accumulation of shares has been motivated entirely by a desire
to take control of the Company’s assets.
“…management have benefited from above-market remuneration…”
This is not true.
Percheron benchmarks
compensation objectively
and is precisely in line
with market
Percheron benchmarks compensation of its Directors and executives
against a fixed group of sixteen comparable companies, being prerevenue, small-cap Australian biotech businesses. For example, in
FY2024, the median salary for the Chief Executive Officers of those
businesses was $475,000. For FY2024, Dr Garner’s salary was $475,000.
Moreover, Dr Garner has voluntarily agreed to defer 50% of his salary
while the Company is going through this transitional period. Dr Gittleson
and Dr Price have also agreed to defer certain Board fees on a similar
basis.
“…without a clear asset or strategy…”
This is not true.
The Board has carefully outlined its strategy to shareholders, including in
its announcements to ASX of 6 January 2025,8 31 January 2025,9 12
8
9
PER Announcement to ASX of 6 January 2025
PER Announcement to ASX of 31 January 2025
Page 10 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
February 2025,10 19 February 2025,11 and 24 February 2025,12 as well as
in various investor webinars, video interview segments, and other
channels. The Board’s strategy is covered in detail elsewhere in this
document.
“Without any meaningful personal shareholdings…”
This is not true.
Percheron directors hold
~48 million shares
In aggregate, the three current Directors hold approximately 48 million
shares of the Company’s stock, representing approximately 4.5% of the
issued share capital. Every share has been purchased out-of-pocket,
either on market or in capital raisings, and not a single share has been
awarded by way of compensation for services. In aggregate, the current
Directors have invested in excess of $730,000 of their personal capital in
the Company over their tenure.
“There is no history or emotional baggage relating to PER with the
incoming directors…”
This is misleading.
For one thing, there is very little history or emotional baggage relating to
Percheron with the current Directors. Each has joined the Board of the
Company comparatively recently: Dr Gittleson in March 2021, Dr Price in
October 2021, and Dr Garner in May 2023.
For another thing, at least one of Powerhouse’s proposed directors is not
a stranger to the Company. In late 2024, the Board explored the
possibility of offering Mr Julian Chick a seat on the Board. He declined
further consideration, pending the phase IIb clinical trial read-out. In
January 2025, after Dr Gittleson’s discussions with Mr McNamee, Mr
Chick was again approached in regard to a Board position, since
Powerhouse had indicated that it may support him as a director. He
again declined, stating that Powerhouse were “the bottom-feeders of the
ASX” and advised the current Directors to “run a mile.”
2.
Observations on Powerhouse’s Proposed Directors
The statement by Powerhouse claims that the three proposed
candidates “possess a strong skill set and track record in biotechnology,
investing and capital markets.” Percheron shareholders should examine
that track record closely.
PER Announcement to ASX of 12 February 2025
PER Announcement to ASX of 19 February 2025
12
PER Announcement to ASX of 24 February 2025
10
11
Page 11 of 21
PERCHERON THERAPEUTICS LIMITED
STAT E M E N T BY T H E B OA R D O F DI R ECTO RS
Doron Eldar
According to his LinkedIn profile, Mr Eldar is currently a director of five
private companies (Electriq~Global, Xerient Pharma, BIGVU Video
Marketing, BridgerPay, and Livia) and two public companies
(Powerhouse and Dotz Nano Limited (ASX: DTZ)). He is also a partner in
two venture capital funds (SIBF and Oxen9). According to many
standards of corporate governance, Mr Eldar would be considered ‘overboarded’ and, were he to be elected to Percheron’s Board, it would be his
eighth concurrent board role. How much of his attention would be
devoted to rebuilding the Company?
Although Mr Eldar claims experience in the healthcare sector by virtue of
these appointments, that experience is not in drug development. Xerient
Pharma is developing a radiotherapeutic product in pancreatic cancer,
while Livia is a device company developing TENS machines for
menstrual cramps. Mr Eldar has no direct experience with the business
in which Percheron is engaged.
Despite his large roster of directorships, Mr Eldar’s experience as a
public company director is also limited. Aside from Powerhouse itself, to
whose Board he was appointed in late 2024, it appears that Dotz Nano
Limited is the only ASX-listed company on whose Board he has served.
The three-year stock price performance of DTZ is shown below:
0.40
0.35
DOTZ NANO LIMITED [DTZ]
77%
0.30
0.25
0.20
0.15
Doran Eldar
Non-Executive Director
Dotz Nano Limited
0.10
0.05
0.00
Richard Hammersley
To the best of the Directors’ knowledge, Mr Hammersley has not
previously served as a public company director and appears to be largely
retired. As noted in Powerhouse’s statement, he was previously the fund
manager for the Endeavour Asset Management
Share your feedback
Discover